Pfizer Gains Traction With Padcev, Lorbrena -- Market Talk
Dow Jones2026/11/03 13:330833 ET - Pfizer says its bet on new products is paying off. In 3Q, revenues of its recently-launched and acquired products grew 32%. Those products include bladder-cancer treatments Padcev, which it acquired, and metastatic non-small cell lung cancer drug Lorbrena, which it developed. Pfizer has been working to develop new medicines and buy other treatments, including weight-loss drugs, as it contends with plummeting demand for its Covid products. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
November 03, 2026 08:33 ET (13:33 GMT)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Arbitrum will welcome a new propAMM
Domestic sales "underperform," PepsiCo (PEP.US) launches mass layoffs of thousands in North America
PepsiCo North America has cut about 1,000 jobs to streamline operations, as beverage sales in the third quarter fell by 2% year-on-year and the full-year profit outlook has been revised downward.
WLFI: Token buyback will be carried out on Aster through a public wallet
Crypto prices
More
